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ABSTRACT      34 
Metastasis is the major cause of cancer-associated death. Partial activation of the epithelial-35 
to-mesenchymal transition (partial EMT) program was considered a major driver of tumour 36 
progression from initiation to metastasis. However, the role of EMT in promoting metastasis 37 
was recently challenged, in particular concerning effects of the Snail and Twist EMT 38 
transcription factors (EMT-TFs) in pancreatic cancer. In contrast, we show here that in the 39 
same pancreatic cancer model driven by Pdx1-cre-mediated activation of mutant Kras and 40 
p53 (KPC-model) the EMT-TF Zeb1 is a key factor for the formation of precursor lesions, 41 
invasion and notably metastasis.  Depletion of Zeb1 suppresses stemness, colonisation 42 
capacity and particularly phenotypic/metabolic plasticity of tumour cells, likely causing the 43 
observed in vivo effects. Accordingly we conclude that different EMT-TFs have 44 
complementary and tissue-specific sub-functions in driving tumours towards metastasis. 45 
Consequently, therapeutic strategies directed at EMT-TFs, should consider such specificities 46 
and target those factors simultaneously. 47 
  48 
3 
Metastasis is still the major cause of cancer-associated death. Partial activation of the 49 
embryonic epithelial-to-mesenchymal transition (partial EMT) program was considered as a 50 
major driver of tumour progression from initiation to metastasis1-3. Most of the studies 51 
involved manipulation of different EMT-inducing transcription factors (EMT-TFs), such as 52 
Snail, Slug, Twist and ZEB1 in cell-culture or xenograft mouse models. Particularly, the EMT 53 
activator ZEB1 was shown to be important for tumourigenicity and metastasis, by triggering 54 
combined activation of cell motility and stemness properties4-6. However, the role of EMT in 55 
invasion and metastasis was challenged by two recent publications using genetic mouse 56 
models for breast and pancreatic cancer7, 8. Particularly, genetic depletion of the EMT-57 
activators Snai1 or Twist1 had no effect on tumour initiation, invasion or metastasis in 58 
pancreatic cancer (PDAC) driven by Pdx1-cre-mediated activation of mutant Kras and p53 59 
(KPC-model)8. Therefore the authors claimed that EMT is dispensable for metastasis. 60 
We here used the same KPC-mouse model for pancreatic cancer and conditionally ablated 61 
the EMT-activator Zeb1 in tumour cells. In contrast to Snai1 and Twist1, depletion of Zeb1 62 
strongly affected formation of precursor lesions, tumour grading, invasion and notably 63 
metastasis during PDAC progression. In summary we conclude that EMT is important for 64 
metastasis, but there is considerable variability and tissue specificity (and not redundancy) in 65 
the role and function of different EMT-TFs. 66 
 67 
RESULTS  68 
Zeb1 depletion reduces grading, invasion and distant metastasis in PDAC  69 
KPC-mice develop metastatic pancreatic cancers with an almost 100% penetrance9. Of note, 70 
a fraction of cancer cells and cells in precursor lesions (PanINs) express the EMT-TF Zeb1, 71 
which was considered to be important for disease progression10, which we could confirm 72 
(Supplementary Fig. 1a and b). To prove the role of Zeb1 in the progression towards 73 
metastasis, we generated a conditional knockout allele of Zeb1 (Zeb1fl) (Fig.1a). Cre-74 
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mediated zygotic deletion of Zeb1 phenocopied the described developmental defects of a 75 
conventional Zeb1 knockout11, thereby confirming its loss-of function12. We crossed the 76 
floxed Zeb1 allele homozygously into KPC mice (Pdx1-cre;KrasLSL.G12D/+;Tp53LSL.R172H/+) to 77 
generate KPC;Zeb1fl/fl mice (termed KPCZ) (Fig. 1a). Progeny were born in expected ratios 78 
and showed no obvious functional defects of the pancreas. Like KPC mice, all KPCZ mice 79 
developed pancreatic cancer. Notably, no significant differences to KPC were detected for a 80 
heterozygous Zeb1 loss (KPC;Zeb1fl/+) (KPCz) (Supplementary Fig. 1c), therefore KPCz 81 
mice were merged with Zeb1 wild type genotypes (KPC) for all analyses. Loss of Zeb1 82 
expression in KPCZ tumour cells was confirmed by immunohistochemistry (Supplementary 83 
Fig. 1b and 2). It was associated with a reduced expression of the EMT activators Zeb2, 84 
Slug, and tentatively also Snail, but the expression frequency of Twist was maintained 85 
(Supplementary Fig. 3a). Depletion of Zeb1 did not delay the onset and only insignificantly 86 
reduced the growth rate of primary tumours (Fig. 1b). In line with this, the number of Ki67+ 87 
proliferating tumour cells, as well as the spontaneous apoptotic rate and the blood vessel 88 
density did not significantly differ (Supplementary Fig. 2). However, Zeb1 deletion strongly 89 
influenced tumour differentiation. Whereas KPC tumours were often high grade and showed 90 
a high intra- and intertumourous heterogeneity, the number of high-grade tumours in KPCZ 91 
animals was strongly reduced and the tumours displayed homogenous, mostly differentiated 92 
phenotypes (Fig. 1c,d, and Supplementary Fig. 1b and 2). Better differentiation was also 93 
associated with a significantly higher Gata6 expression (Supplementary Fig. 3b), which is a 94 
marker for higher differentiation and better clinical prognosis of human PDAC13. KPCZ mice 95 
showed an increased deposition of extracellular matrix (Supplementary Fig. 2). Future work 96 
will address this aspect, since the different composition of the stroma in pancreatic cancer 97 
can be associated with increased14, 15 or reduced16, 17 aggressiveness. 98 
Next we analysed whether depletion of Zeb1 affects malignant tumour progression. Primary 99 
KPCZ tumours showed markedly lower local invasion (Fig. 1d). Of note, differentiated KPC 100 
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tumours also often underwent a de-differentiation associated with upregulation of Zeb1 101 
expression in invasive tumour cells. This was not detected in KPCZ tumours, a first sign for 102 
reduced plasticity in Zeb1-depleted cancer cells (Fig. 1e). A major finding was that the 103 
capacity for distant metastasis was strongly reduced in KPCZ tumours (Fig. 1f, 104 
Supplementary Table 1). Thereby the corresponding metastases showed a histology and 105 
Zeb1 expression state similar to that of the primary tumor (Fig. 1g and Supplementary Fig. 106 
3c). In summary, Zeb1 depletion strongly reduced progression towards highly malignant, 107 
metastatic pancreatic tumours. This is in stark contrast to depletion of Snai1 or Twist1 in the 108 
same model, which did not affect malignant tumour progression8.  109 
 110 
Zeb1 depletion reduces stemness, tumourigenic and colonisation capacities  111 
To further investigate the consequences of Zeb1 depletion, we isolated primary tumour cells 112 
from KPC and KPCZ mice. In agreement with the strong heterogeneity of the KPC primary 113 
tumours, corresponding tumour cells displayed highly variable phenotypes from 114 
mesenchymal, to mixed and epithelial. This was evident from the growth patterns, as well as 115 
the expression of epithelial and mesenchymal marker genes (Fig. 2a-d and Supplementary 116 
Fig. 4a). In contrast all tumour lines derived from KPCZ mice were fixed in an epithelial state 117 
with strongly reduced mesenchymal gene expression. However, despite the strong 118 
phenotypical differences between KPC and KPCZ-derived cancer cell lines, we detected no 119 
consistent difference in proliferation (Fig. 2e). Accordingly, the sensitivity to the 120 
chemotherapeutic agent gemcitabine, which targets proliferating cells, was variable, but not 121 
consistently changed between KPC and KPCZ cancer cells. This was also the case for two 122 
pancreatic cancer cell lines isolated from KPC tumours with depletion of Snai1 (KPCS) 123 
(Supplementary Fig. 4b). KPCZ cells were tentatively more resistant to the EGFR inhibitor 124 
erlotinib, but we did not detect a significant difference between KPC and KPCS cells. Upon 125 
s.c. grafting into syngeneic mice at high injection dose (1 x 105 cells), all KPC and KPCZ cell 126 
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lines gave rise to tumours mimicking the differentiation state of the cell line and the growth 127 
pattern of the corresponding primary tumour, supporting the in vitro data on differentiation 128 
and proliferation (Supplementary Fig. 4a,c,d).  129 
Strikingly, although all tumour cell lines did not show significant changes in proliferation and 130 
were able to grow subcutaneously, the lung colonisation capacity after intravenous injection 131 
was almost completely eradicated for all KPCZ cell lines (Fig. 3a). This was not due to 132 
differences in the capability to reach the lung, since there was no significant reduction of 133 
disseminated cancer cells in the lung (Fig. 3b and Supplementary Fig. 5a). Notably, in 134 
comparison to KPCZ lines, genetic depletion of Snai1 (KPCS cells) had no effect on lung 135 
colonisation capacity (Fig. 3c), confirming data by Zheng et al.8. This goes along with 136 
considerably high, albeit varying levels of Zeb1 expression in the KPCS lines, which might 137 
explain the maintained colonisation capacity. The relevance of Zeb1 expression even at 138 
reduced levels was further demonstrated in KPC cells after partial depletion of Zeb1 to 30-139 
50% of the original levels, which did not significantly affect the lung colonisation capacity 140 
(Fig. 3d).  141 
Since crucial traits for distant colonisation include stemness and tumourigenicity, we tested 142 
these features. Tumourigenicity of the cell lines was significantly reduced in KPCZ cell lines, 143 
particularly when compared to the KPC cell lines with a similar epithelial phenotype 144 
(Supplementary Fig. 5b). Interestingly within the KPC cell lines the epithelial differentiated 145 
cells had a higher tumourigenic capacity compared to mesenchymal type cell lines. This is in 146 
agreement with data showing that the plasticity of re-epithelialisation is important to some 147 
degree for tumourigenic and colonisation capacity and that non-plastic mesenchymal cells do 148 
not efficiently metastasize18-20. In addition, depletion of Zeb1 almost completely reduced the 149 
sphere forming capacity, a surrogate test for stemness competence (Fig. 3e and 150 
Supplementary Fig. 5c). Analysis of established marker combinations21 for human pancreatic 151 
cancer stem cells displayed no significant differences for CD24/CD44 and CD133. Epcam, 152 
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another marker was not applicable, since it is a direct target of Zeb1 repression22 and thus 153 
strongly upregulated in KPCZ cells (Supplementary Fig. 5d). This is in line with data showing 154 
that human PDAC stemness markers are not applicable in the KPC model23. However, the 155 
stem cell marker Sox2 turned out to be completely absent in KPCZ cell lines and s.c. grafted 156 
tumours in comparison to KPC cell lines (Fig. 3f,g). Strongly reduced Sox2 expression upon 157 
Zeb1 depletion was also reflected in the primary KPC tumours (Supplementary Fig. 2). Sox2 158 
expression was proposed to be stabilized by Zeb1, through its reciprocal feedback loop with 159 
miR-200 family members24. We confirmed this hypothesis by showing that miR-200c, which 160 
is strongly upregulated in KPCZ cell lines (Fig. 2c), suppressed both Zeb1 and Sox2 161 
expression in KPC cell lines (Fig. 3h). These data are of particular relevance since Sox2 162 
expression is enhanced in aggressive subtypes of human PDACs25-27. Together our data 163 
indicate that Zeb1 increases the tumourigenic capacity and is crucial for colonisation of 164 
distant organs. Moreover, depletion of Zeb1 is again in stark contrast to a depletion of Snai1 165 
or Twist1, which did not affect the tumourigenic and colonisation capacity.  166 
According to this data we wondered, why we did not see an effect on the primary tumour-free 167 
survival in KPCZ mice (Fig. 1b). It is known that mutant p53 boosts tumour progression by 168 
inducing a mutator phenotype28, 29. In addition it was shown that mutant p53 overcomes a 169 
growth arrest in pancreatic cancer30. Thus we speculated that once a precursor lesion is 170 
formed, the progression towards a highly proliferating tumour is too fast to detect changes in 171 
the initial tumourigenic capacity. Therefore we analysed mutant Kras mice without the p53 172 
mutant allele (Pdx1-cre;KrasLSL.G12D/+, termed KC). These mice develop slowly progressing 173 
acinar-ductal metaplasia (ADM)- as well as PanIN-precursor lesions, which also express 174 
Zeb110. In contrast to KPCZ, KC mice with homozygous deletion of Zeb1 (termed KCZ) 175 
showed a strongly reduced number and grading of PanIN and ADM lesions (Fig. 4a,b and 176 
Supplementary Fig. 6a). This data further indicates that Zeb1 triggers the tumourigenic 177 
capacity in pancreatic cancer from initial development till late stage metastasis. 178 
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 179 
Zeb1 is crucial for cancer cell plasticity  180 
Zeb1 does not affect expression of single genes or small gene clusters but thousands of 181 
genes, leading to a complete reprogramming of cells31 and we have shown that Zeb1 exerts 182 
pleiotropic effects on many different programs and pathways31-33. Therefore we performed a 183 
global gene expression analysis to examine the impact of Zeb1 on cell plasticity. A principal 184 
component analysis (PCA) showed a clear separation of KPC- and KPCZ-cell lines and a 185 
separation of the epithelial and mesenchymal phenotype along the first (PC1) and second 186 
principal component (PC2), respectively (Fig. 5a). The latter verified the initial findings that a 187 
depletion of Zeb1 fixes the cells in a homogenous epithelial state, indicating that Zeb1 is a 188 
critical factor underlying cell heterogeneity and potentially also plasticity. In line with the PCA, 189 
a gene set enrichment analysis (GSEA) confirmed that Zeb1 depletion shifts the cells 190 
towards an epithelial phenotype (Supplementary Fig. 6b). Moreover, loss of Zeb1 expression 191 
enriches for genes associated with addiction to Kras expression34, reduced metastastic 192 
competence35, as well as the “classical” subtype of human PDACs, which have the best 193 
clinical prognosis36 (Fig. 5b). We further analysed the expression of genes strongly 194 
associated with metastatic progression, including Pdgfrb, which is essential to drive 195 
metastasis in pancreatic cancer together with mutant p5337. All of the analysed genes were 196 
expressed in KPC cell lines, but strongly downregulated upon Zeb1 depletion (Fig. 5c). 197 
However, in agreement with the heterogeneous phenotypes, these pro-metastatic genes 198 
were expressed only at low levels in KPC tumour cells with epithelial differentiation, although 199 
these cell lines had the highest lung colonisation capacity. We hypothesized that epithelial 200 
KPC cells possess enough plasticity to adapt their gene expression. 201 
Enhanced plasticity of cancer cells is considered an important driving force of malignant 202 
tumour progression by allowing continuous adaptions to the demanding conditions in the 203 
changing tumour environment1, 38, 39. We have previously demonstrated that ZEB1, 204 
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particularly through its feedback loop with miR-200 family members, is a motor of cellular 205 
plasticity in response to extracellular cues4. Thus, we hypothesized that the presence of 206 
Zeb1 allows adaptations of gene expression patterns and that loss of cellular plasticity is an 207 
important consequence of Zeb1 depletion in cancer cells. We tested this hypothesis by 208 
treating KPCZ cells with TGFβ1, a driver of malignant tumour progression and prominent 209 
inducers of EMT40, 41. As expected, upon TGFβ treatment KPC cells with an epithelial 210 
phenotype underwent an EMT. However, even after long-term TGFβ treatment KPCZ cells 211 
maintained their epithelial phenotype (Fig. 6a,b and Supplementary Fig. 7a). Thus without 212 
Zeb1, the cells were locked in their phenotypic state and lost plasticity. Loss of plasticity was 213 
also reflected in TGFβ-induced changes in global gene expression, where in contrast to KPC 214 
cell lines with an epithelial phenotype, the epithelial KPCZ cell lines displayed a strongly 215 
reduced responsiveness to TGFβ (Fig. 6c). The PCA showed an induction of a mesenchymal 216 
phenotype only of the KPC cell lines under TGFβ stimulation along the first principal 217 
component (PC1). Among the 20,052 analysed genes, 1514 were significantly regulated 218 
upon long-term TGFβ treatment (Fig. 6c and Supplementary Table 2), however, 1,377 (91%) 219 
of them depended on the genetic presence of Zeb1. The genes associated with metastatic 220 
progression including Pdgfrb, which were not present in epithelial KPC cells, were also 221 
upregulated by TGFβ in a Zeb1-dependent manner (Fig. 6d). These data also indicate that 222 
Zeb1 is important for a large fraction of TGFβ induced changes. The Zeb1-dependent TGFβ 223 
induced genes also included genes, which we recently identified as common Zeb1/Yap 224 
target genes upregulated in aggressive cancer types (Supplementary Fig. 7b)31. The high 225 
Zeb1 dependent plasticity was further indicated by the fact that Zeb1 associated phenotypic 226 
and gene expression changes were reversible after withdrawal of TGFβ (Fig. 6e-g).  227 
Another important aspect in cancer cell biology is metabolics. Tumour cells show a high 228 
metabolic plasticity in reacting to environmental changes on their way to metastasis42. We 229 
exemplified this by modulating the two basic energy consumption pathways: glycolysis and 230 
10 
oxidative phosphorylation (OxPhos). As measured in a mito stress test, KPCZ cells have a 231 
lower basal respiration and respiration-related ATP production as indication of reduced 232 
OxPhos (Fig.7a), which is also visible in a glycolysis stress test (Fig. 7b). Blocking of OxPhos 233 
by oligomycin in a glycolysis stress test forces cells to exploit their glycolytic capacity for 234 
fulfilling energy demands and demonstrates a considerable glycolytic reserve in KPC cells 235 
(Fig. 7b). However, this glycolytic switch was no longer possible in KPCZ cells owing to a 236 
complete lack of a glycolytic reserve. Thus, also the plasticity in switching between basic 237 
energy pathways and adapting to different oxygen availability was strongly dependent on the 238 
expression of Zeb1.  239 
Finally, high phenotypic plasticity of epithelial KPC cells was also detected in vivo after 240 
grafting into syngeneic mice. Although they displayed a differentiated phenotype in central 241 
tumour regions, KPC tumour cells underwent a de-differentiation associated with an 242 
upregulation of Zeb1 at the invasive front. In contrast grafted KPCZ cell lines displayed no 243 
phenotypic plasticity, but were fixed in their differentiated state (Fig. 7c and Supplementary 244 
Fig. 7c). Altogether, the data indicate that Zeb1 is very important for cellular plasticity in 245 
cancer cells. 246 
 247 
DISCUSSION  248 
Here, we describe a key role for the EMT-TF Zeb1 in the in vivo progression of pancreatic 249 
cancer from early precursor lesions towards metastasis. Genetic depletion of Zeb1 in the 250 
pancreas reduces formation of ADM and PanIN precursor lesions, undifferentiated (high 251 
grade) carcinomas, invasion and metastasis. In isolated primary cancer cell lines Zeb1 252 
ablation leads to loss of cellular plasticity and fixation in an epithelial phenotype, a likely 253 
cause of reduced stemness, tumourigenicity and colonisation capacities (Table 1).  254 
 255 
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Our data demonstrate that Zeb1 acts in strong contrast to the EMT-TFs Snail and Twist in 256 
pancreatic cancer. Snai1 or Twist1 depletion in the same KPC-model did not affect formation 257 
of PanINs, tumour differentiation, invasion, colonisation and importantly metastasis8. Based 258 
on their results, Zheng et al. claimed that EMT is dispensable for metastasis. However, our 259 
data favour a different interpretation and allow a more comprehensive picture of the effect of 260 
EMT-TFs in tumours. Our results point to functional differences of EMT-TFs and demonstrate 261 
that Zeb1 stimulates pancreatic tumour progression from formation of precursor lesions to 262 
late stage metastasis.  263 
 264 
What could be the critical functions of Zeb1? Its regulatory potential is not limited to effects 265 
on a few crucial downstream target genes, but rather leads to a global reprogramming of 266 
gene expression patterns 31 and does not only control EMT but also other programs and 267 
pathways. One of the most striking consequences of Zeb1 depletion was the almost 268 
complete inhibition of lung colonisation. We postulate two major effects of Zeb1 inactivation 269 
as the underlying molecular mechanism: the block in cellular plasticity, considered as a major 270 
driving force of tumour progression towards metastasis and the reduction of stemness, a 271 
crucial property underlying tumourigenicity and colonisation. Enhanced plasticity of cancer 272 
cells impresses as ongoing transitions between an undifferentiated/(partial) mesenchymal 273 
and a differentiated/epithelial phenotype1, 38, 39, 43, 44. We here describe a central role of Zeb1 274 
in exerting different aspects of cellular plasticity, particularly the response to TGFβ, but also 275 
to metabolic changes and changes in the in vivo intratumourous heterogeneity. Differentiated 276 
KPC as well as KPCZ cancer cells only expressed low levels of metastasis-associated 277 
genes. However, only KPC cells, but not KPCZ cells, were able to activate their expression 278 
upon TGFβ treatment. These genes include Pdgfrb, which was recently shown to be 279 
absolutely required for metastasis in p53-mutant pancreatic cancer37. As a side effect, our 280 
finding that absence of Zeb1 strongly reduces the number of TGFβ-regulated genes 281 
12 
indicates that Zeb1 is important for a large part of the TGFβ response (Supplementary Table 282 
2). Furthermore, Zeb1-linked plasticity is exemplified by its impact on central metabolic 283 
pathways. The plasticity in switching between basic energy pathways is strongly 284 
compromised in Zeb1-depleted cells, displaying both a reduced OxPhos and reduced 285 
glycolytic reserve, which might also be critical for the colonisation step. In addition Zeb1 286 
inactivation affects stemness and tumourigenic properties, supporting the view that EMT-287 
MET dynamics also reflects the plasticity between stemness and a differentiated state45, 46. 288 
Particularly the strong reduction of the stem cell factor Sox2 in KPCZ tumours and derived 289 
cell lines is of high relevance, since its expression was correlated with stemness, plasticity 290 
and progression in pancreatic and other cancer types25-27. Together, our data indicate that 291 
Zeb1 is crucial for cellular plasticity and stemness/tumourigenic properties in pancreatic 292 
cancer cells.  293 
 294 
There are several potential reasons, why particularly Zeb1 is associated with cellular 295 
plasticity. Firstly, Zeb1 is linked in a reciprocal double-negative feedback loop with members 296 
of the mir-200 family, which controls a switch between an undifferentiated/stemness and a 297 
differentiated phenotype4. Secondly, the Zeb1 gene itself has a poised, bivalent chromatin 298 
configuration, allowing a rapid switch between high expression in cancer stem cells (CSCs) 299 
and low expression in non-CSCs47. Moreover, we are beginning to understand functional 300 
differences between Zeb1 and other EMT-TFs at the biochemical level. For instance, we 301 
have described a direct interaction of ZEB1 with the Hippo-pathway effector YAP1, which is 302 
crucial for activating a common ZEB1/YAP1 target gene set important for tumour 303 
progression31. Genes of this target set can be activated by TGFβ in epithelial KPC cells, but 304 
not in KPCZ cells. Notably, as demonstrated here for Zeb1, also Yap1 was shown to be 305 
important for the progression through ADM towards pancreatic carcinoma48, 49. 306 
 307 
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Zeb1-dependent gene expression signatures also point to a clinical relevance of our findings. 308 
Zeb1 ablation associates with tumours of the ‘classical subtype’ of pancreatic cancer, which 309 
has the best clinical prognosis compared to other subtypes36, 50. These data fit to the reduced 310 
aggressiveness of KPCZ tumours and further support data showing that Zeb1 expression 311 
correlates with more aggressive precursor lesions and poor outcome in human pancreatic 312 
cancer24, 51, 52. Moreover, KPCZ cells show enrichment of a gene signature associated with 313 
KRAS-addiction. Notably, in this study absence of ZEB1 was already a determinant of 314 
KRAS-dependency34, 53. Thus, although KRAS bears the key mutation in pancreatic cancer54, 315 
expression of Zeb1 might render cancer cells independent of mutant KRAS. 316 
 317 
However, our findings also raise additional questions. Firstly, why did we not observe a 318 
significant effect of Zeb1 depletion on primary tumour-free survival in KPCZ mice (Fig. 1b)? 319 
When we omitted the mutant p53 allele, Zeb1 was critical for the formation of Kras-driven 320 
ADM and PanIN lesions as its depletion strongly reduced their occurrence. Similar data were 321 
recently shown in the MMTV-PyMT model of breast cancer, where Snail was important for 322 
tumour initiation and progression in a p53 wild type but not p53 mutant context55. Thus our 323 
data support the hypothesis that in the context of mutant p53 the progression towards a 324 
highly proliferating tumour is too fast to allow detection of changes in initial tumourigenicity.  325 
Secondly, why did we detect metastases in KPCZ animals at all? The fact that Zeb1 loss 326 
reduces the metastatic competence to approximately 30% shows that Zeb1-associated EMT 327 
and plasticity is strongly supporting metastasis. Nevertheless, it also indicates a Zeb1-328 
independent, albeit less efficient metastasis formation, which might include a potential partial 329 
redundancy with remaining EMT-TFs, although at a significantly lower efficacy. Another 330 
explanation could be different routes to metastasis, which likely cooperate with EMT-TF 331 
dependent mechanisms to various extents. As already postulated, different routes may 332 
emerge by acquisition of additional genetic alterations driving metastasis independent of 333 
14 
cellular plasticity-associated traits1, 56. Again, mutated p53 might enhance the generation of 334 
such a genetically driven metastasis30. In this light, the fact that Zeb1 depletion efficiently 335 
reduces plasticity, colonisation and metastasis even in the context of mutant p53 is 336 
remarkable and further supports the importance of Zeb1 as a crucial driver of tumour 337 
progression. 338 
 339 
In conclusion we demonstrated that the EMT-TF Zeb1 is a key driver of pancreatic tumour 340 
progression from early tumourigenesis to late stage metastasis, underscoring the important 341 
role of EMT-activation in these processes. By contrast, Snail and Twist were shown to be 342 
dispensable for metastasis in this cancer type, indicating that EMT-TFs have specific sub-343 
functions, which are not redundant but complementary. Non-redundant sub-functions of 344 
EMT-TFs were already described, e.g. for Zeb1 and Zeb2 in melanoma57, 58, for Snail and 345 
Slug in breast cancer59, as well as for Sox460 and Prrx119. Moreover sub-functions can be 346 
tissue specific, as demonstrated by the different roles of Snail in metastasis of breast61 and 347 
pancreatic cancer8. Consequently, therapeutic strategies directed at EMT-TFs, should 348 
consider these specificities and target such factors simultaneously.  349 
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 534 
FIGURE LEGENDS 535 
 536 
Figure 1: Zeb1 depletion reduces invasion and metastasis in pancreatic cancer. 537 
(a) Scheme of the genetic mouse models for pancreatic cancer. The colour code (blue 538 
KPC, red KPCZ) is used for all results. (b) Tumour-free survival (n= 28 KPC, 18 KPCZ; 539 
Log-rank (Mantel-Cox) test), tumour volume (0 = start of MRI measurements; n=23 KPC, 540 
19 
27 KPCZ; error bars show mean ±S.E.M.; multiple t-tests with correction for multiple 541 
comparison using the Holm-Sidak method). n.s. = not significant. (c) Representative HE-542 
stained sections for the grading of the respective tumours. Scale bar, 250 µm and 125 543 
µm for higher magnifications. (n=48 KPC, 29 KPCZ  independent tumours) (d) Grading 544 
and local invasion of the respective tumours (n=48 KPC, 29 KPCZ independent tumours; 545 
error bars show mean ±S.D.; Mann-Whitney test (two-tailed), Chi-square test (two-tailed) 546 
for grade3/4 tumours), ****p<0.0001. (e) Representative immunohistochemical stainings 547 
of consecutive sections showing nuclear Zeb1 in tumour cells (arrows) of invasive 548 
tumour regions in KPC, but not in KPCZ mice. Asterisks mark Zeb1 expression in 549 
stromal cells, cen (central) and inv (invasive tumour regions). n= 15 KPC, 13 KPCZ 550 
independent tumours, Scale bar, 75 µm. (f) Numbers and grading of metastasized 551 
tumours (n=52 KPC, 29 KPCZ independent tumours; error bars mean ±S.D.; Chi-square 552 
test (two-tailed) for metastasis, Mann-Whitney test (two-tailed) for grading). (g) 553 
Representative images of differentiated (KPC and KPCZ) and undifferentiated (KPC) 554 
primary tumours (PT) and corresponding metastases (Met) with the same phenotype (L= 555 
liver). n= 19 KPC, 4 KPCZ independent tumours and corresponding metastases. Scale 556 
bar, 150 µm. 557 
 558 
Figure 2: Depletion of Zeb1 affects phenotypic variability of tumour cells. 559 
(a) Anti-E-cadherin and anti-vimentin immunofluorescence stainings showing variable 560 
expression in KPC cell lines and homogeneous E-cadherin and lack of vimentin 561 
expression in all KPCZ cell lines. Scale bar, 100 µm. (b) Relative mRNA expression 562 
levels of indicated marker genes in the isolated tumour cells. (c) Relative mRNA 563 
expression levels for EMT transcription factors and epithelial microRNAs. mRNA levels 564 
of the cell line 661 was set to 1. n=3 biologically independent experiments, error bars 565 
mean ±S.E.M. *p<0.05, **p<0.01, n.s. = not significant, Mann-Whitney test (one-tailed) 566 
(b-c). (d) Immunoblots of indicated marker genes (unprocessed scans of immunoblots 567 
are shown in Suppl. Fig. 8). (e) BrdU proliferation assay for the isolated tumour cell lines. 568 
n=3 biologically independent experiments, error bars mean ±S.E.M. The colour code for 569 
the isolated cell lines as depicted in b) is valid for all corresponding results. 570 
 571 
Figure 3: Depletion of Zeb1 affects stemness, tumourigenic and colonisation 572 
capacities. 573 
20 
(a) Representative images of macroscopic and HE-stained lungs, 18 days after i.v. 574 
injection of tumour cells in syngeneic mice. Quantification of lung colonies (left, cell lines 575 
grouped by genotype; right, individual cell lines (for a,b,c,e), normalised to 20 mm2 lung 576 
area). n=3mice/cell line, n=4 mice for line 524, error bars mean ±S.D.; ****p<0.0001, 577 
Mann-Whitney test (two-tailed), Scale bar, 200 µm. (b) No. of GFP+ cells per visual field 578 
2 h after i.v. injection. n=3 mice/cell line, error bars mean ±S.D. Mann-Whitney test (two-579 
tailed). (c) Quantification after i.v. injection of KPC, KPCS and KPCZ tumour cells in 580 
nude mice; n=13 mice for KPC, n=8 for KPCS, n=6 for KPCZ- 4 mice/cell line, Mann-581 
Whitney test (two-tailed), **p<0.01, n.s. = not significant. Relative mRNA expression 582 
levels in KPCS cell lines; mRNA levels of KPC661 (expressing low levels of Snail) set to 583 
1; average of n=2 biologically independent experiments, error bars mean ±S.D. 584 
Immunoblot for the indicated proteins with KPC701 as control expressing high Snail 585 
levels. (d) Number of lung colonies after i.v. injection of KPC shcontrol (ctr) and KPC 586 
shZeb1 tumour cells in nude mice (normalized to 20 mm2 lung area). n= 3 mice/cell line, 587 
error bars mean ±S.D.; Mann-Whitney test (two-tailed), n.s = not significant. 588 
Immunoblots and corresponding quantifications, showing shRNA-mediated partial 589 
reduction of Zeb1. n=3 biologically independent experiments, error bars mean ±S.E.M.; 590 
unpaired Student’s t-test (two-tailed), **p<0.01. (e) Quantification of sphere forming 591 
capacity. n=3 biologically independent experiments, error bars mean ±S.D.; *p<0.05, 592 
Mann-Whitney test (two-tailed). (f) Relative mRNA expression levels and immunoblots of 593 
stem cell genes. mRNA levels of the line 661 set to 1. n=3 biologically independent 594 
experiments, error bars mean ±S.E.M. *p<0.05, Mann-Whitney test (one-tailed). (g) HE 595 
and immunohistochemical staining for Sox2 in tumours grown subcutaneously (s.c.) 596 
(n=51) or in the lung (n=36) after i.v. injection (l.c.) of indicated cell lines. Scale bar, 100 597 
µm. (h) Immunoblot for indicated proteins upon overexpression of Mir200c. Source data 598 
for Fig. 3c, d, f see Supplementary Table 5; unprocessed scans of immunoblots are 599 
shown in Suppl. Fig. 8.  600 
 601 
Figure 4: Depletion of Zeb1 reduces ADM and PanIN precursor lesions. 602 
(a-b) Consecutive sections of representative HE and PAS stained sections showing 603 
precancerous PanIN (a) and ADM lesions (b) in the pancreas of 6 month old KC and 604 
KCZ mice. Specific dark blue/purple PAS staining indicates the mucin-rich PanIN 605 
lesions, arrows indicate ADMs. Squares mark the magnified regions; Scale bars 1 mm 606 
and 150 µm for higher magnifications in (a) and 75 µm in (b). Quantification of the ADM 607 
21 
and PanIN areas and PanIN grading is given. n=12 KC and 7 KCZ independent mice, 608 
error bars mean ±S.D.; **p<0.01, ****p<0.0001 unpaired Student’s t-test (two-tailed) with 609 
Welch’s correction for ADM and PanIN areas and Mann-Whitney test (two-tailed) for 610 
grading.  611 
 612 
Figure 5: Depletion of Zeb1 reduces phenotypic variability  613 
(a) Principal component analysis (PCA) of the KPC and KPCZ cell line transcriptomes. 614 
The plot depicts the first two principal components using all samples accounting for 615 
~44%, ~17% of the variance, respectively. (b) Gene set enrichment analyses (GSEA) of 616 
transcriptome data from KPCZ vs. KPC cells reveal enrichment of gene signatures 617 
associated with Kras dependency and the classical type of pancreatic cancer, as well as 618 
a reduction of genes associated with metastasis in KPCZ cell lines. NES=normalized 619 
enrichment score; FDR=false discovery rate. (c) Relative mRNA expression levels (qRT-620 
PCR) and immunoblots of indicated genes associated with metastasis in the isolated 621 
tumour cells. mRNA levels of the cell line 661 was set to 1. n=3 biologically independent 622 
experiments, error bars mean ±S.E.M. *p<0.05, **p<0.01, Mann-Whitney test (one-623 
tailed). Unprocessed scans of immunoblots are shown in Suppl. Fig. 8.  624 
 625 
 626 
Figure 6: Depletion of Zeb1 reduces TGFβ-induced cellular plasticity. 627 
(a) E-cadherin and vimentin immunofluorescence staining of two epithelial KPC and two 628 
KPCZ cancer cell lines treated with TGFβ1 for 3 and 21 days. Scale bar, 100 µm. (b) 629 
Immunoblots for indicated marker genes of the same lines as in a). Unprocessed scans 630 
of immunoblots are shown in Suppl. Fig. 8. (c) PCA of transcriptome signatures of the 631 
KPC and KPCZ cell lines upon TGFβ treatment. TGFβ -induced shifts in expression of 632 
the cell lines shown in a) are marked with coloured boxes (microarrays performed in 633 
duplicates, referred to as TGFβ_1 and TGFβ_2). Note, a great shift for KPC cell lines 634 
towards a mesenchymal pattern but not for KPCZ lines(upper panel). Venn diagram 635 
showing number of significantly up-or downregulated genes (cut-off: adj. p-value<0.05 636 
and log2FC>0.5) by 14 days of TGFβ treatment of cell lines shown in a). Moderated t-637 
test (lower panel). (d) Relative mRNA expression levels (qRT-PCR) of indicated genes 638 
(including the metastasis set in Fig. 5c) in KPC and KPCZ cell lines treated for different 639 
times with TGFβ (time points: 0, 6 h, 1, 3, 7, 14, 21 days). mRNA levels of the cell line 640 
661 at day 0 were set to 1. n=3 biologically independent experiments, error bars mean 641 
22 
±S.E.M. Statistical analysis is shown for the comparison of TGFβ treated and untreated 642 
samples (grey bars) of each individual cell line *p<0.05, **p<0.01, unpaired Student’s t-643 
test (one-tailed). (e) Anti-E-cadherin and anti-vimentin immunofluorescence staining of 644 
two epithelial KPC and two KPCZ cancer cell lines treated with TGFβ for more than 21 645 
days followed by 14 days TGFβ withdrawal. Scale bar, 100 µm. (f-g) Immunoblots (f) 646 
and relative mRNA expression levels (qRT-PCR) (g) of indicated marker genes of the 647 
same cell lines as in e). mRNA levels of the cell line 661 at day 0 were set to 1. n=3 648 
biologically independent experiments, error bars mean ±S.E.M.; *p<0.05, **p<0.01, 649 
***p<0.001, unpaired Student’s t-test (one-tailed). Source data for Fig. 5d,f see 650 
Supplementary Table 5; unprocessed scans of immunoblots are shown in Suppl. Fig. 8.  651 
 652 
Figure 7: Depletion of Zeb1 reduces metabolic and phenotypic plasticity. 653 
(a) Mito stress test (MST) showing the oxygen consumption rate (OCR) as indicator for 654 
oxidative phosphorylation and deduced levels for basal respiration and ATP production. 655 
(b) Glycolysis stress test (GST) showing the extracellular acidification rate (ECAR) as 656 
indicator for glycolysis and the OCR after glucose stimulation, blocking of oxidative 657 
phosphorylation with oligomycin and blocking of glycolysis with 2-deoxy-glucose (2DG), 658 
as well as deduced glycolytic capacity and glycolytic reserve. Note a complete lack of a 659 
glycolytic reserve (upper arrow) after blocking oxidative phosphorylation (lower arrow) in 660 
KPCZ cells. KPC661 and 792 as well as all KPCZ cell lines were used. n=7 biologically 661 
independent experiments; error bars ±S.E.M. for MST and GST and ±S.D. for other 662 
parameters; for MST and GST a multiple t-test with correction for multiple comparison 663 
using the Holm Sidak method was used; for other parameters an unpaired Students’s t-664 
test (two-tailed) was used; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (c) 665 
Representative images of consecutive sections of immunohistochemical stainings for 666 
Ck19 and Zeb1 comparing the plasticity of Zeb1 expression in central and invasive 667 
tumour regions. Shown are tumours derived from one KPC and one KPCZ cell line. 668 
Asterisks label Zeb1 expression in stromal cells, arrows indicate Zeb1-positive tumour 669 
cells at the invasive front. Ck19 expression is shown to identify cancer cells. n= 15 KPC, 670 
13 KPCZ independent tumours, Scale bars, 50 µm and 150 µm for higher 671 
magnifications.  672 
 673 
Table 1: Summary of the differential behaviour of KPC vs. KPCZ cell lines 674 
concerning crucial traits for tumour progression towards metastasis. 675 
23 
Table summarizing the experimental results of the differential behaviour of KPC vs. 676 
KPCZ cell lines concerning crucial traits for tumour progression towards metastasis. For 677 
experimental data on sphere formation see Figs. 3e, Suppl. Fig. 5c; tumorigenicity see 678 
Suppl. Fig. 5b; plasticity see Figs. 6 and 7, Suppl. Fig. 7a,c; lung colonisation see Fig. 679 
3a; lung dissemination see Fig. 3b, Suppl. Fig. 5a. ( -, no capacity; +, weak capacity; ++, 680 
moderate capacity; +++, strong capacity; na, not analysed). 681 
 682 
 683 
 684 
 685 
 686 
METHODS 1 
 2 
Ethic statement 3 
Animals were kept on a 12:12 h light-dark cycle and provided with food and water ad libitum. 4 
Animal husbandry and all experiments were performed according to the European Animal 5 
Welfare laws and guidelines. The protocols were approved by the committee on ethics of 6 
animal experiments of the states Baden-Württemberg and Bavaria (Regierungspräsidium 7 
Freiburg and Regierung Unterfranken, Würzburg). 8 
Mice 9 
The Pdx1-Cre transgene (Tg(Pdx1-cre)6Tuv), the conditional KrasLSL.G12D (Krastm4Tyj) , 10 
Tp53LSL.R172H (Trp53tm2Tyj) and GFP (Z/EG; Tg(CAG-Bgeo/GFP)21Lbe) alleles and the KPC 11 
mouse model have been described9, 62-66 and were kept on a C57BL/6 background. The 12 
generation of the conditional Zeb1 knockout allele (Zeb1fl) is described elsewhere12. In brief, 13 
exon6 was flanked by loxP sites to remove sequences coding for large parts of the protein 14 
and to induce a premature translational stop. Tumour mice were generated by breedings of 15 
Pdx1-Cre with KrasLSL.G12D/+;Tp53LSL.R172H/+ mice (KPC) and Pdx1-Cre;Zeb1fl/fl with 16 
KrasLSL.G12D/+;Tp53LSL.R172H/+;Zeb1fl/fl mice (KPCZ). KPC and KPCZ offspring was palpated 17 
weekly for tumour initiation and enrolled for MRI measurements when tumours were 18 
identified. KC and KCZ mice (Tp53+/+ genotype) were analysed with 6 months of age. Once 19 
the tumour reached a maximum tolerated size (tumour diameter of 1 cm), mice were 20 
sacrificed, perfused and organs, tumour and macroscopic metastases were isolated. 21 
Animals, which died or were sacrificed due to non-pancreatic tumour reasons (mainly growth 22 
of skin papilloma) were excluded from the analyses. Tissue was fixed in 4% 23 
paraformaldehyde (PFA) or snap frozen in TissueTek. A summary of basic tumour mice data 24 
is shown in Supplementary Table 1. 25 
MRI 26 
1 
Mice were analysed with a Brucker Bio Spin 94/20, 9.4Tesla – 400MHz – 20cm small animal 27 
MR using coronal and transverse scans with a spatial resolution of 117 µm x 117 µm/pixel 28 
and a 256 x 256 matrix. Slice distance was set to 0.5 mm. Measurements were repeated 29 
weekly. Tumour volume was approximated by π/6 x l x w x d. Initial detection of a tumour 30 
after a series of tumour-free MRI measurements was defined as time-point of tumour 31 
initiation. For analysis of tumour growth curves all mice were adjusted to a tumour size of 50 32 
mm3. 33 
Histology, histopathology and immunohistochemistry 34 
PFA-fixed tissues were embedded into paraffin, sectioned at 4-5µm and stained with Mayer’s 35 
Haematoxylin and Eosin solution G (HE). For histopathological scoring, tumours were 36 
classified using the standard pathological grading scheme into either well differentiated 37 
(grade 1), moderately differentiated (grade 2), poorly differentiated (grade 3) and anaplastic 38 
or sarcomatoid (grade 4). The histological invasion score was scored from no invasion (0) to 39 
high invasion (2), with invasion defined as number and distance of tumour cells disseminated 40 
from the main tumour mass. Masson’s trichrome staining (MTS) was performed according to 41 
the manufacturer’s instructions (Sigma-Aldrich, HT15) and counterstained by Weigert’s Iron 42 
Haematoxylin. Tumour stroma composition was scored either based on MTS or HE staining 43 
for intensity of extracellular matrix deposition on a scale from 0-4. KC and KCZ pancreata 44 
were stained by alcian blue-periodic acid/Schiff’s (PAS) reagent. Scoring for CD31 and 45 
Gata6 was done according to staining intensity with no (0), low (1), medium (2) and high (3) 46 
expression. PanINs were classified using the standard pathological grading score from 1-3. 47 
The complete numbers of PanINs and ADMs was counted on at least four independent 48 
tumour sections and normalized to a tissue area of 20 mm2. In addition to macroscopic 49 
metastases, lungs and livers were screened for metastases identified by screening four 50 
series of HE stained sections separated by at least 200 µm. 51 
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Immunohistochemical analysis was performed as previously described31. Primary antibodies 52 
against the following proteins were used: polyclonal rabbit anti-Zeb1 (Novus Biological, 53 
NBP1-05987, 1:250); polyclonal rabbit anti-Zeb2 (Novus Biological, NBP1-82991, 1:200); 54 
monoclonal rabbit anti-Snail (Cell Signaling, #3879, Clone C15D3, 1:200); monoclonal rabbit 55 
anti-Slug (Cell Signaling, CS9585, Clone C19G7, 1:150); polyclonal goat anti-Twist (Abcam, 56 
ab50581, 1:500); polyclonal goat anti-Gata6 (R&D, AF1700, 1:1500); monoclonal mouse 57 
anti-E-Cadherin (BD Transduction Laboratories, 610182, Clone 36, 1:350); monoclonal rabbit 58 
anti-CD31 (Santa Cruz, sc-1506, Clone M-20, 1:50); monoclonal rabbit anti-Ki67 (Abcam, 59 
ab16667, Clone SP6, 1:300); monoclonal rabbit anti-cleaved Caspase 3 (Cell Signaling, 60 
CS9664, Clone 5A1E, 1:1,000); monoclonal rat anti-KRT19 (TROMA-3 hybridoma 61 
supernatant,1:20, a kind gift from Rolf Kemler); polyclonal rabbit anti-Sox2 (Abcam, ab97959, 62 
1:1,000) and counterstained with Mayer’s Haematoxylin. For Zeb1 immunofluorescence 63 
staining, cryosections were fixed in 4% PFA for 10 min, then permeabilised for 10 min in 64 
0.25% Triton-X100/PBS. After blocking in 3% BSA/PBS, tissue was incubated with anti-Zeb1 65 
antibody (Sigma, HPA027524, 1:100) followed by Alexa594-conjugated secondary antibody 66 
(Life technologies). All images were acquired on a Leica DM5500B microscope and a 2D 67 
deconvolution was performed when appropriate. No statistical method was used to 68 
predetermine sample size and the experiments were not randomized. Histological analyses 69 
were performed by two independent pathologists. The Investigators were not blinded to 70 
allocation during experiments and outcome assessment. Each demonstrated IHC and IF 71 
image was representative for minimum five or more cases (tumours) of indicated subtype. 72 
Primary cell lines 73 
A small piece of primary tumour was dissected, minced with a scalpel and plated on 6-well 74 
plates in DMEM (Gibco, 31966)/ 10%FBS (Gibco, 10500)/ 1%P/S (Gibco, 15140) at 37°C/5% 75 
CO2 in a humidified incubator. Tumour cells that attached to the plate and grew out were 76 
passaged for generation of cell lines. Successful and complete recombination of cell line 77 
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deprivation was confirmed by PCR. KPCS cells were obtained from Dieter Saur (Dept. of 78 
Internal Medicine, TU Munich, Germany) and generated from the same KPC mouse model 79 
that additionally carried a homozygous Snai1 deletion67. For partial knockdown of Zeb1, cells 80 
were infected with lentivirus containing a pGIPZ shZeb1 knockdown (V2LMM_18639) or a 81 
pGIPZ non-silencing shRNA control construct. Puromycin resistant GFP medium/high cells 82 
were used. Zeb1 protein expression was normalized to β-actin levels using BioRad 83 
ImageLab Software to calculate knockdown efficiencies. Induction of EMT in primary tumour 84 
cell lines was performed by adding 5 ng/ml TGFβ1 (PeproTech, 100-21) and replacing the 85 
medium daily for the duration of the experiment. miRNA overexpression was performed as 86 
previously described31. For FACS analysis of cancer stem cells markers 1x106 cells were 87 
incubated with a combination of monoclonal rat anti-CD24-PE (BD, 553262, Clone M1/69, 88 
1:200), monoclonal rat anti-CD44-APC (BD, 561862, Clone IM7, 1:100) and monoclonal rat 89 
anti-Epcam-FITC (ebioscience, 11-5791, Clone G8.8, 1:200) antibodies and analysed in a 90 
BD Cytoflex using CytExpert software. A total of 10,000 vital cells were counted. All studies 91 
were performed on cells cultured for less than 30 passages. All experiments using primary 92 
cells in vitro were done at least in triplicates (n=3). Only primary cells from mouse tumours 93 
were used and these were not further authenticated nor tested for mycoplasma 94 
contamination.  95 
Immunoblotting, RNA isolation and quantitative RT-PCR 96 
Protein was extracted with RIPA buffer and Western blotting was carried out as described31, 97 
32 with the exception that protein detection on the nitrocellulose membrane was done by 98 
incubation in Western Lightning Plus-ECL (Perkin Elmer, NEL103001EA) or SuperSignal 99 
West Femto Maximum Sensitivity Substrate (Thermo Scientific, 34095) and a ChemiDoc 100 
imaging system (BioRad). Antibodies against the following proteins were used: polyclonal 101 
rabbit anti-Zeb1 (Sigma, HPA027524, 1:5000); monoclonal rabbit anti-Snail (Cell Signaling, 102 
#3879, Clone C15D3, 1:1000); monoclonal mouse anti-E-Cadherin (BD Transduction 103 
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Laboratories, 610182, Clone 36, 1:5000); monoclonal mouse anti-N-Cadherin (BD 104 
Transduction Laboratories, 610920, Clone 32, 1:1,000); monoclonal rabbit anti-Vimentin (Cell 105 
Signaling, CS5741, Clone D21H3, 1:5,000); monoclonal mouse anti-ß-actin (Sigma, A5441, 106 
Clone AC-15, 1:10,000); polyclonal rabbit anti-Sox2 (Novus Biological, NB110-37235, 107 
1:3,000); monoclonal mouse anti-Bmi1 (Millipore, 05-673, Clone F6, 1:300); monoclonal 108 
rabbit anti-PDGFRß (Cell Signaling, CS3169, Clone 28E1, 1:1,000); monoclonal rabbit anti-109 
Sparc (Cell Signaling, CS8725; Clone D10F10, 1:1,000); monoclonal mouse anti-α-tubulin 110 
(Sigma, T6199, Clone DM1A, 1:5000). Western blots were done for at least three individual 111 
experiments and one representative blot is shown. 112 
Total RNA was isolated and reversely transcribed using the RNeasy Plus Mini Kit (Qiagen, 113 
74136) and the RevertAid First Strand cDNA Synthesis Kit (Thermo, K1622) for mRNA and 114 
the miRCURY universal cDNA synthesis kit II (Exiqon, 203301) for miRNA. mRNA transcripts 115 
were detected by using cDNA from 7.5 ng total RNA with 300 nM gene-specific primers, the 116 
Universal Probe Library (Roche, 04869877001) and the TaqMan Universal Master Mix 117 
(4440040, Applied Biosystems) in a 12 µl volume. miRNAs were analysed with the 118 
miRCURY ExiLENT SYBR Green Kit (Exiqon, 203421) with specific primer sets (Exicon) 119 
according to the manufacturer’s instructions. All samples were run in a LightCycler 480 120 
(Roche) and values were normalised to Gapdh and Mir16-1 levels where appropriate and 121 
expressed relative to controls. For primer sequences and miR primer set details see 122 
Supplementary Table 3.  123 
Cell viability (MTT) and BrdU cell proliferation assays 124 
Cell viability upon gemcitabine (Sigma, G6423; ranging from 0.78 to 1000 nM) and erlotinib 125 
treatment (Cell Signaling, 5083 or Selleckchem, S1023, ranging from 0.2 to 51.2 µM) was 126 
analysed by plating 6,000 cells in 96- or 48-well plates and measured after 72 h of treatment 127 
using 5 mg/ml MTT (methylthiazolyldiphenyl-tetrazolium bromide; Sigma, M2128) as 128 
described68. IC50 values were calculated with GraphPad Prism using logarithmic transformed 129 
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data and nonlinear regression. For proliferation analysis 1,000 cells were plated in 96-well 130 
plates and BrdU incorporation was measured after a 2-h pulse with BrdU using the Cell 131 
Proliferation ELISA Kit (Roche, 11647229001) according to the manufacturer’s instructions. 132 
Sphere assay 133 
For detecting sphere forming capacity, cells were resuspended as single cell suspension in 134 
serum-free DMEM/F12 medium (Gibco, 31331), containing 1% methylcellulose (Sigma, 135 
M0512), 20 ng/ml human EGF (R&D Systems, 236-EG), 20 ng/ml human FGF (BD 136 
biosciences, 354060), B27 supplement (1:50, Invitrogen, 17504), N2 supplement (1:100, 137 
Gibco, 17502), and 1% P/S. 500 single cells were seeded into individual wells of a poly(2-138 
hydroxyethylmetacrylate)-coated (Sigma, P3932) 96-well plates. Colonies with a diameter of 139 
>80 µm were counted after 12 days. 140 
Immunofluorescence staining 141 
Immunofluorescence labelling was performed as described previously31. Cells were seeded 142 
on coverslips and fixed with 4% PFA, followed by permeabilization with 0.1% Triton X-143 
100/PBS. After blocking in 3% BSA/PBS, cells were incubated with primary antibodies 144 
overnight at 4°C (polyclonal rabbit anti-Zeb1 (Sigma, HPA027524, 1:300); monoclonal 145 
mouse anti-E-Cadherin (BD Transduction Laboratories, 610182, Clone 36, 1:200), followed 146 
by appropriate Alexa594- and Alexa488-conjugated secondary antibodies (Life technologies) 147 
for 1 hour at RT. All images were acquired with a Leica DM5500B microscope and the LAX 148 
software (Leica). All IF experiments were performed in at least three individual experiments 149 
and one representative image is shown. 150 
Lung colonization/tumourigenicity 151 
Tumour cell colonisation and metastasising capacities to the lung were analysed by tail vein 152 
injections into syngeneic mice or NMRI-Foxn1nu/nu mice. Primary tumour cell lines were 153 
trypsinised and resuspended in appropriate volumes of PBS to inject 200,000 tumour cells in 154 
a 200 µl volume using a 27G needle. Mice were sacrificed after 18 days and analysed for 155 
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lung metastasis by HE staining. For each cell line three mice were injected and the number 156 
or lung metastases were counted on 2 independent sections separated by at least 200 µm. 157 
For short-term colonisation analysis cells were infected with pCDH-MSCV-LUC_EF1-GFP-158 
T2A-Puro, selected by puromycin and sorted for medium to high levels of GFP expression. 159 
After tail vein injection mice were sacrificed after 2 h. For calculating tumourigenicity and 160 
analysis of tumour growth upon subcutaneous engraftment 500, 2,500, 12,500 and 100,000 161 
cells were injected into flanks of C57BL/6 mice. Tumour size was measured 3 times per 162 
week and mice were sacrificed if tumours exceeded the size of 500 mm³ or ulcerated. 163 
Tumour initiating frequencies were calculated using the ELDA software 164 
(http://bioinf.wehi.edu.au/software/elda/). 165 
Microarray analysis, pre-processing, GSEA and data availability 166 
Gene expression of three epithelial, three mesenchymal KPC, six KPCZ, two TGFβ-treated 167 
epithelial KPC and two TGFβ-treated KPCZ cell lines was measured using Illumina Mouse 168 
WG6 v2 beadarrays (Illumina, San Diego, CA, USA). Total RNA was isolated, labelled and 169 
hybridised according to the manufacturer’s protocol in two separate experiments. Raw 170 
microarray data were processed and quantile normalised using the Bioconductor R package 171 
beadarray69 and subsequently batch corrected according to their chip identity via ComBat70 172 
as implemented in the R Bioconductor sva package. Illumina probes were mapped to Entrez 173 
IDs using the IlluminaMousev2 annotation (v. 1.26) from Bioconductor. If several probes 174 
mapped to the same Entrez ID, the one having the largest interquartile range was retained, 175 
which resulted in 20,052 uniquely annotated genes. Gene Set Enrichment analysis (GSEA) 176 
was performed using the Broad Institute platform 177 
(http://www.broadinstitute.org/gsea/index.jsp; Version 2.2.2). A total of 189 gene sets of the 178 
oncogenic signature C6 from the Molecular Signatures database 179 
(http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=C6) were used for the 180 
analysis with default settings and 1,000 gene set permutations. Additionally 36 gene sets, 181 
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related to pancreatic cancer, Zeb1 or metastasis were selected from MSigDB and also 182 
analysed (Supplementary Table 4). Gene Sets from classical, quasi-mesenchymal and 183 
exocrine-like PDAC subtypes were obtained from Collisson et al. 201136.  184 
Metabolic parameters 185 
Bioenergetics of epithelial KPC and KPCZ cell lines was determined using the XFe96 186 
Extracellular Flux Analyzer (Seahorse Bioscience/Agilent Technologies, North Billerica, MA). 187 
Cells were seeded in specialised cell culture microplates at a density of 15,000 /well and 188 
cultured for 18 h. 1 h before the measurement cells were incubated at 37°C in a CO2-free 189 
atmosphere. For the determination of glycolytic parameters a glycose stress test was 190 
performed: basal extracellular acidification rate (ECAR; indicative of glycolysis) was first 191 
determined under glucose-free conditions. Secondly, the rate of glycolysis was calculated 192 
using the ECAR after glucose supplementation (10 mM). Finally, glycolytic capacity and 193 
glycolytic reserve were calculated after inhibition of mitochondrial respiration via oligomycin 194 
(Sigma, 75351, 1 µM) and hexokinase activity via 2-deoxy-glucose (2DG, Sigma, D6134, 100 195 
mM). ). For the determination of respiratory parameters a mito stress test was performed: 196 
basal oxygen consumption rate (OCR, indicator for mitochondrial respiration) was measured. 197 
Next, responses toward the subsequent addition of oligomycin (1 µM), FCCP (Sigma, C2920, 198 
1 µM) and the combination of antimycin A (Sigma, A8674, 3 µM) and rotenone (Sigma, 199 
R8875, 3 µM) were evaluated allowing for the calculation of basal and maximal respiration as 200 
well as respiration-related ATP production. All experiments were performed in heptaplicates. 201 
Statistics and Reproducibility 202 
Statistical analysis was performed using GraphPad Prism software (Version 6.07). Data are 203 
represented by means ±SD unless otherwise indicated. For survival analysis the log-rank 204 
Mantel-Cox test was used. Tumour/PanIN grading, ECM deposition, local invasion, CD31 205 
and Gata 6 staining, Ki67-positive tumour cell counting, cleaved Casp3-positive tumour cell 206 
amounts, PanIN areas, lung colonisation assay and sphere forming capacity analysis were 207 
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tested for significance with a two-tailed Mann-Whitney test or an unpaired two-tailed t-test as 208 
indicated. A Welch’s correction was performed where appropriate. Chi-square analysis was 209 
performed to compare frequencies of metastases and number of tumour-initiating cells as 210 
well as frequency of Zeb1, Snail, Slug, Twist Zeb2, E-cad and Sox2 positive tumours. 211 
Tumour growth, ECAR and OCR were tested for significance at individual time points by a t-212 
test with Holm-Sidak test for multiple comparison. qPCR data were tested for significance 213 
with a one-tailed Mann-Whitney test or an unpaired one-tailed t-test as indicated. p-values of 214 
statistical significance are represented as: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 215 
Data Availability 216 
Microarray data generated in this study have been deposited in the Gene Expression 217 
Omnibus (GEO) under accession code GSE87472. The 189 publically available gene sets 218 
reanalysed here were from of the oncogenic signature C6 available from the Molecular 219 
Signatures database (http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=C6, 220 
Broad Institute, 741 MSigDB, Version 5.1.). The 36 publically available gene sets related to 221 
pancreatic cancer, Zeb1 or metastasis were selected from MSigDB and reanalysed here 222 
(see also Supplementary Table 4). Gene Sets from classical, quasi-mesenchymal and 223 
exocrine-like PDAC subtypes re-analysed here were obtained from Collisson et al. 201136.  224 
Source data for Fig. 3c,d,f; Fig. 6d,g and Supplementary Fig. 5d, 7a have been provided as 225 
Supplementary Table 5. All other data supporting the findings of this study are available from 226 
the corresponding author on reasonable request. 227 
 228 
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